executive impact

Takeda CEO prescribes surgical R&D cuts after Shire deal

2 Comments
By Ben Hirschler

The requested article has expired, and is no longer available. Any related articles, and user comments are shown below.

© (c) Copyright Thomson Reuters 2018.

©2024 GPlusMedia Inc.

2 Comments
Login to comment

Such deals usually have more to do with CEO hubris than good economic sense, and this one looks a case in point. They invariably destroy shareholder value (like the deal creating GSK did).

0 ( +0 / -0 )

Login to leave a comment

Facebook users

Use your Facebook account to login or register with JapanToday. By doing so, you will also receive an email inviting you to receive our news alerts.

Facebook Connect

Login with your JapanToday account

User registration

Articles, Offers & Useful Resources

A mix of what's trending on our other sites